Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 10, Number 1, January 2018, pages 22-26

Safety of Landiolol Hydrochloride as a Premedication for Producing an Appropriate Heart Rate for Multidetector-Row Computed Tomography Coronary Angiography

Figure

Figure 1.
Figure 1. (a) HR upon entry to the CT room, before the injection of landiolol hydrochloride, after injection at the time of the CTA scan and after the CTA scan in all patients. (b) The patients were divided into three groups according to HR upon entry to the CT room: 70 - 79 bpm (n = 76, dotted line), 80 - 89 bpm (n = 60, gray line) and ≥ 90 bpm (n = 40, solid line) groups. *P < 0.01 vs. upon entry to the CT room.

Tables

Table 1. Patient Characteristics
 
BMI: body mass index; HTN: hypertension; SBP: systolic blood pressure; DBP: diastolic BP; DM: diabetes mellitus; FBS: fasting glucose; HbA1c: hemoglobin A1c; DL: dyslipidemia; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; CAD: coronary artery disease; LVEF: left ventricular ejection fraction.
Age, years67 ± 11
Gender (male), n (%)64 (36%)
BMI, kg/m224.1 ± 3.7
Smoking, n (%)53 (30%)
Family history, n (%)52 (30%)
HTN, n (%)116 (66%)
  SBP/DBP, mm Hg131 ± 25/77 ± 15
DM, n (%)37 (21%)
  FBS, mg/dL106 ± 24
  HbA1c, %6.0 ± 1.0
DL, n (%)107 (61%)
  LDL-C, mg/dL117 ± 32
  HDL-C, mg/dL58 ± 16
  TG, mg/dL131 ± 81
CKD, n (%)20 (11%)
  eGFR, mL/min/1.73 m267 ± 14
CAD, n (%)69 (39%)
LVEF, %65 ± 8

 

Table 2. Medications (n = 176)
 
ARB/ACE-I: angiotensin II receptor blocker/angiotensin converting enzyme inhibitor; CCB: calcium channel blocker; DPP4-I: dipeptidyl peptidase-4 inhibitor.
ARB/ACE-I, n (%)62 (35%)
Diuretic, n (%)13 (7%)
β-blocker, n (%)3 (2%)
CCB, n (%)73 (41%)
Statin, n (%)61 (35%)
DPP4-I, n (%)25 (14%)
Insulin, n (%)4 (2%)